1-(2-溴甲氧基)-2,4-二氯苯 | 6954-77-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-溴甲氧基)-2,4-二氯苯
• 中文别名: 1-(2-溴乙氧基)-2,4-二氯苯
• 英文名称: 1-(2-bromoethoxy)-2,4-dichlorobenzene
• 英文别名: 2-(2,4-Dichlorphenoxy)-ethylbromid；1-bromo-2-(2,4-dichlorophenoxy)-ethane
• CAS: 6954-77-4
• 化学式: C₈H₇BrCl₂O
• mdl: MFCD00043464
• 分子量: 269.953
• InChiKey: OEYZGSRLAGSENP-UHFFFAOYSA-N

物化性质

• 沸点：
  175-179 °C (10 mmHg)
• 稳定性/保质期：
  避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S37,S39
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 储存条件：
  密封储存，应存放在阴凉干燥的库房中。

SDS

Name:	1-(2-Bromoethoxy)-2 4-dichlorobenzene Material Safety Data Sheet
Synonym:
CAS:	6954-77-4

Section 1 - Chemical Product MSDS Name:1-(2-Bromoethoxy)-2 4-dichlorobenzene Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6954-77-4	1-(2-Bromoethoxy)-2,4-dichlorobenzene	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6954-77-4: Personal Protective Equipment Eyes: Wear chemical splash goggles and face shield.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 175 - 179 deg C @10mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >200 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7BrCl2O
Molecular Weight: 269.95

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
No information found.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6954-77-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Bromoethoxy)-2,4-dichlorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6954-77-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6954-77-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6954-77-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-溴甲氧基)-2,4-二氯苯 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-(2,4-二氯-苯氧基)-乙胺
  参考文献：
  名称：

  Julia,M.; de Rosnay,J., Chimica Therapeutica, 1969, vol. 4, p. 334 - 343

  摘要：

  DOI：
• 作为产物：
  描述：

  2 - (2,4-二氯苯氧基)乙醇 在 三溴化磷 作用下， 以 乙二醇二甲醚 为溶剂， 反应 20.0h， 生成 1-(2-溴甲氧基)-2,4-二氯苯
  参考文献：
  名称：

  EP1380562

  摘要：

  公开号：

文献信息

• Method of treating lipidemia with aryloxyalkylaminobenzoic acids and
  申请人：American Cyanamid Company

  公开号：US04182776A1

  公开（公告）日：1980-01-08

  Aryloxyalkylaminobenzoic acids and esters as hypolipemic compounds.

  芳氧烷基氨基苯甲酸和酯作为降脂化合物。
• Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)
  作者：Xiaoke Guo、Xianglei Ma、Qian Yang、Jing Xu、Lu Huang、Jianmin Jia、Jiaojiao Shan、Li Liu、Weilin Chen、Hongxi Chu、Jinlian Wei、Xiaojin Zhang、Haopeng Sun、Yiqun Tang、Qidong You

  DOI：10.1016/j.ejmech.2014.03.075

  日期：2014.6

  and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。
• Synthesis of New 1,4-Diarylimidazoles and 1-Aryl-4-(5-Nitrofuran-2-il)imidazoles and Study of Their Anti-Infective Activity
  作者：T. A. Kuzmenko、L. N. Divaeva、A. S. Morkovnik、Yu. V. Koshchienko、A. A. Zubenko、Yu. D. Drobin、L. N. Fetisov、A. N. Bodryakov

  DOI：10.1134/s1068162018050096

  日期：2018.11

  1-R-3-acylmethylbenzimidazolium salts have been obtained which transformed under the action of ammonium acetate into the previously undescribed 1,4-diarylimidazoles and 1-aryl-4- (5-nitrofuran-2-il)imidazoles. The antiprotozoal, fungistatic, and antimicrobial activities of these compounds have been tested.

  使用 1-R-苯并咪唑和 ω-溴苯乙酮或 2-溴乙酰-5-硝基呋喃，已获得相应的 1-R-3-酰基甲基苯并咪唑季盐，其在乙酸铵的作用下转化为先前未描述的 1,4-二芳基咪唑和 1-芳基-4-(5-硝基呋喃-2-il)咪唑。已经测试了这些化合物的抗原生动物、抑真菌和抗微生物活性。
• Synthesis, Biological Activity Evaluation and Molecular Modeling Study on the New Isoconessimine Derivatives as Acetylcholinesterase Inhibitors
  作者：Guofei Jin、Zhongduo Yang、Weiwei Xue、Jie Sheng、Yin Shi、Xiaojun Yao

  DOI：10.1002/cjoc.201300441

  日期：2013.9

  110 nmol/L which is close to that of reference compound huperzine A (IC50=70 nmol/L). The mode of AChE inhibition by 7b was reversible and non‐competitive. In addition, molecular modeling was performed to explore the binding mode of inhibitor 7b at the active site of AChE and the results showed that 7b could be docked into the acetylcholinesterase active site and compound 7b had hydrophobic interactions

  新的异cosnessimine衍生物是从conessine（1）合成的，并被评估为乙酰胆碱酯酶（AChE）抑制剂。衍生物是通过两个反应步骤（N-去甲基化和亲核取代）制备的。所有合成的衍生物均显示出比Conessine（1）（IC 50 = 16 µmol·L -1）和异椰油亚胺（2）（IC 50 > 300 µmol·L -1）更高的潜在抗乙酰胆碱酯酶活性。化合物7b（3β- [甲基-[2- [4-（4-硝基苯氧基）乙基]氨基] con-5-烯酸）对IC 50的抑制作用最强110 nmol / L的浓度接近参考化合物石杉碱A的浓度（IC 50 = 70 nmol / L）。7b抑制AChE的模式是可逆的，并且是非竞争性的。此外，进行分子建模以探索抑制剂7b在AChE活性位点的结合方式，结果表明7b可以与乙酰胆碱酯酶活性位点对接，化合物7b与Trp279和Leu282发生疏水相互作用。
• Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists
  作者：Miguel Guerrero、Mariangela Urbano、Jian Zhao、Melissa Crisp、Peter Chase、Peter Hodder、Marie-Therese Schaeffer、Steven Brown、Hugh Rosen、Edward Roberts

  DOI：10.1016/j.bmcl.2011.10.096

  日期：2012.1

  potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure–activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1–3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility

  S1P 4受体 (S1P 4 -R) 的高亲和力和选择性小分子激动剂可能在包括自身免疫性疾病、病毒感染和血小板减少症在内的多种疾病领域具有重要的治疗效用。分子库-小分子库库的高通量筛选 (HTS) 鉴定出 3-(2-(2,4-dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine 是一种中等效力和选择性的 S1P 4 -R击中激动剂。HTS 衍生命中的设计、合成和系统的结构-活性关系研究导致了新型强效 S1P 4 -R 激动剂的开发，该激动剂对剩余的 S1P 1-3,5 具有极好的选择性-Rs 家庭成员。值得注意的是，本文报道的分子提供了新的药理学工具来破译生物学功能并评估 S1P 4 -R的治疗效用。

表征谱图